GlassScriptPrepare for your visit
Thomas Nattakom
Gastroenterology (Internal Medicine) · Las Cruces, NM · NPI 1598711475
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$6,829.53
in general payments reported to CMS, 2019-2025 · $1,659 in 2025
The $1,659 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Who reported paying
General payments only, top 6 by amount.
- Janssen Biotech, INC. $1,600.24
- Abbvie INC. $1,571.43
- Salix Pharmaceuticals, A Division of Bausch Health US, LLC $904.97
- Pfizer INC. $478.82
- Takeda Pharmaceuticals U.S.A., INC. $343.83
- Gilead Sciences, INC. $283.54
Drugs and devices associated with these payments
Stelara Skyrizi Tremfya Rinvoq Velsipity Xifaxan Simponi Simponi Aria Entyvio Voquezna Ibsrela Xeljanz
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Thomas Nattakom listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/1293506/thomas-nattakom